ibrutinib added to autosct conditioning and consolidation for patients with abc-dlbcl
Published 6 months ago • 66 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
1:44
triangle: ibrutinib with soc or as a substitute to autologous transplantation in first-line mcl
-
1:17
ibrutinib & chemotherapy (teddi-r) in the treatment of secondary cns lymphoma
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
1:13
rationale for combining ibrutinib with tisa-cel in mcl
-
7:28
1 year post hsct :)
-
9:02
martin dreyling, md: efficacy of first-line ibrutinib in mcl
-
26:46
webinar recording | technology advances in hematology testing | sparrc 2021 by srmc | mindray india
-
3:21
enhancing autologous cellular therapy with ibrutinib in cll patients
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
2:18
the combination of ibrutinib and obinutuzumab in cll
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
2:23
zilo-301: phase iii study of zilovertamab ibrutinib vs ibrutinib in r/r mcl
-
8:57
outcomes of sct in t-all and t-lbl
-
1:37
causes & management of ibrutinib discontinuation in cll
-
2:41
an overview of the latest advances in hematology
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll